Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 445 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Unfractionated Heparin Clear all
Completed Phase 3 Interventional

Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer

NCT00003674
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Veno-occlusive Disease
Interventions
dalteparin, standard therapy
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
19
States / cities
Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 18, 2026, 2:45 AM EDT
Not listed Phase 4 Interventional

Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban

NCT04169269
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Thromboembolism
Interventions
Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters, Rivaroxaban 10 milligram Oral Tablet
Drug
Lead sponsor
Florida Orthopaedic Institute
Network
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 18, 2026, 2:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients

NCT04042324
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Triferic, Heparin
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 18, 2026, 2:45 AM EDT
Completed Phase 4 Interventional Results available

Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO

NCT03318393
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation Complication, Pediatric ALL, Anticoagulants
Interventions
Bivalirudin, Unfractionated heparin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
1 Day to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Oct 18, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

NCT01839487
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
PEGPH20, Nab-paclitaxel, Gemcitabine, Dexamethasone, Enoxaparin
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
51
States / cities
Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 18, 2026, 2:45 AM EDT
Recruiting Phase 2 Interventional

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428
View directory record Official record
Conditions
Carcinoma, Non-small-Cell Lung
Interventions
Amivantamab, Lazertinib, Carboplatin, Pemetrexed, Direct Oral Anticoagulant (DOAC), Low Molecular Weight Heparin (LMWH)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
26
States / cities
La Jolla, California • Orange, California • Stanford, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 18, 2026, 2:45 AM EDT
Completed Phase 4 Interventional

Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)

NCT00289042
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Enoxaparin
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2007 · Synced Oct 18, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Results available

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

NCT00986154
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism, Venous Thrombosis
Interventions
edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
8,292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
82
States / cities
Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 18, 2026, 2:45 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin

NCT02206100
View directory record Official record
Conditions
Healthy
Interventions
PER977, Placebo, enoxaparin
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 18, 2026, 2:45 AM EDT
Completed Not applicable Interventional Results available

Comparison of Two Pulmonary Embolism Treatments

NCT05684796
View directory record Official record
Conditions
Pulmonary Embolism Acute
Interventions
Anticoagulation, mechanical aspiration thrombectomy
Drug · Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Tucson, Arizona • Los Angeles, California • Lakeland, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 18, 2026, 2:45 AM EDT
Not listed Phase 2 Interventional

Heparin Intraoperative Instillation for Lower Urinary Tract Symptoms After Benign Hysterectomy

NCT03633994
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Postoperative Urinary Tract Infection
Interventions
Heparin, Normal saline
Drug
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 18, 2026, 2:45 AM EDT
Terminated Not applicable Interventional Results available

Feasibility of ExAblate MRI Guided High Intensity Focused Ultrasound Tx of Soft Tissue Tumors

NCT01965002
View directory record Official record
Conditions
Soft Tissue Neoplasms
Interventions
MRgHIFU, Aspirin, Enoxaparin
Device · Drug
Lead sponsor
Pejman Ghanouni
Other
Eligibility
10 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 18, 2026, 2:45 AM EDT
Completed Early Phase 1 Interventional

Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients

NCT00894283
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin, Fondaparinux
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2019 · Synced Oct 18, 2026, 2:45 AM EDT
Completed Phase 1 Interventional

CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

NCT02995655
View directory record Official record
Conditions
Myelodysplastic Syndromes, Acute Myeloid Leukemia, AML, MDS
Interventions
CX-01, Azacitidine, Bone marrow biopsy, Peripheral blood draw
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 18, 2026, 2:45 AM EDT
Withdrawn Phase 2 Interventional

A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia

NCT01048177
View directory record Official record
Conditions
Vulvodynia
Interventions
Bladder instillation with heparin/ lidocaine
Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 18, 2026, 2:45 AM EDT
Terminated Not applicable Interventional

Efficacy and Safety of Ethanol Lock Therapy for the Prevention of Central Line-associated Bloodstream Infections

NCT02890875
View directory record Official record
Conditions
Catheter-Related Infections
Interventions
Ethanol lock, Heparin lock
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Oct 18, 2026, 2:45 AM EDT
Terminated Phase 3 Interventional

Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial

NCT02448550
View directory record Official record
Conditions
Percutaneous Coronary Intervention
Interventions
Bivalirudin, Unfractionated heparin
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 18, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)

NCT00786474
View directory record Official record
Conditions
Arterial Thromboembolic Events, Atrial Fibrillation
Interventions
Placebo, Dalteparin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1,884 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Oct 18, 2026, 2:45 AM EDT
Completed No phase listed Observational

IMproved PREdiction of Severe Sepsis in the Emergency Department

NCT01392508
View directory record Official record
Conditions
Systemic Inflammatory Response Syndrome (SIRS), Sepsis, Severe Sepsis, Septic Shock
Interventions
Not listed
Lead sponsor
Axis Shield Diagnostics Ltd
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 18, 2026, 2:45 AM EDT
Completed Phase 2Phase 3 Interventional

Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)

NCT04372589
View directory record Official record
Conditions
COVID-19, Pneumonia
Interventions
Heparin
Drug
Lead sponsor
University of Manitoba
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Atlanta, Georgia • Chicago, Illinois • Jefferson, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 18, 2026, 2:45 AM EDT
Withdrawn Phase 4 Interventional

Is Using Fondaparinux (Blood Thinner) to Treat Lung Clot Cheaper Than Traditional Therapy

NCT00377091
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Fondaparinux
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 18, 2026, 2:45 AM EDT
Completed Phase 3 Interventional

Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement

NCT00332020
View directory record Official record
Conditions
Prevention, Venous Thromboembolism
Interventions
Rivaroxaban (BAY59-7939), Enoxaparin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
2,457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Birmingham, Alabama • Denver, Colorado • Bay Pines, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 18, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma

NCT03339349
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolus
Interventions
Enoxaparin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 18, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention

NCT01522417
View directory record Official record
Conditions
Myocardial Infarction, Acute Coronary Syndromes, Unstable Angina
Interventions
Short Tirofiban, Eptifibatide, Long Tirofiban
Drug
Lead sponsor
Medicure
Industry
Eligibility
18 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
13
States / cities
Kissimmee, Florida • St. Petersburg, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 18, 2026, 2:45 AM EDT